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Introduction
Carcinogenesis, caused by physical, chemical, or viral mech-
anisms, is a multistage process of coordinated acquisition 
of favorable genetic lesions and complex interactions between 
tumor and host tissues that ultimately leads to an aggressive 
metastatic phenotype (Hanahan and Weinberg, 2000). A mouse 
skin carcinogenesis model was well-established by applica-
tion of 7,12-dimethylbenz(a)-anthracene (DMBA) and 12-O-
tetradecanoylphorbol-13-acetate (TPA). DMBA is an initiator, 
whereas TPA is a classic tumor promoter. In this model, activa-
tor protein-1 (AP-1) activation appears to play a causal role in 
skin tumor promotion (Young et al., 1999). The AP-1 transcrip-
tion factor family consists of 18 different combinations of Jun-
Jun or Jun-Fos proteins as well as the closely related ATF and 
MAF transcription factors. The Jun family of proteins includes 
c-Jun, JunB, and JunD, whereas the Fos family of proteins 
includes c-Fos, FosB, Fra-1, and Fra-2 (Shaulian and Karin, 
2001). The c-jun and c-fos genes are inducible by a broad range 
of extracellular stimuli. Upon activation, AP-1 binds to TPA-
response elements 5′-TGAG/CTCA-3′ to transactivate many 
effector genes, thus regulating cell proliferation, tumor promo-
tion, cell cycle progression, growth arrest, and apoptosis (Angel 
and Karin, 1991).
AP-1 was fi  rst considered as a mediator of tumor promo-
tion because of its ability to alter gene expression in response to 
tumor promoters such as TPA and UV irradiation (Angel and 
Karin, 1991). Indeed, TPA and UV, as well as reactive oxygen 
species, activate AP-1 (Dhar et al., 2002). Both TAM67- and 
c-fos–defi  cient mice have been used to establish the role of AP-1 
in skin carcinogenesis induced by UV and DMBA/TPA (Saez 
et al., 1995; Young et al., 1999; Cooper et al., 2003). TAM67 is 
a transactivation domain deletion mutant of c-Jun that acts to 
sequester Jun and Fos family proteins in low activity complexes 
(Dong et al., 1994). Overexpression of TAM67, driven by a K14 
promoter, reduces AP-1 activity and dramatically inhibits the 
formation of tumors induced by DMBA/TPA (Young et al., 
1999), as well as of squamous cell carcinoma induced by UV 
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ensitive to apoptosis gene (SAG)/regulator of 
cullins-2–Skp1-cullin–F-box protein (SCF) E3 ubiqui-
tin ligase regulates cellular functions through ubiqui-
tination and degradation of protein substrates. We report 
that, when expressed in mouse epidermis driven by the 
K14 promoter, SAG inhibited TPA-induced c-Jun levels 
and activator protein-1 (AP-1) activity in both in vitro 
primary culture, in vivo transgenic mice, and an AP-1–
luciferase reporter mouse model. After AP-1 inactivation, 
epidermal proliferation induced by 7,12-dimethylbenz(a)-
  anthracene/12-O-tetradecanoylphorbol-13-acetate at the 
early stage of carcinogenesis was substantially inhibited. 
Later stage tumor formation was also substantially inhib-
ited with prolonged latency and reduced frequency of 
  tumor formation. Interestingly, SAG expression increased 
tumor size, not because of accelerated proliferation, but 
caused by reduced apoptosis resulting, at least in part, 
from nuclear factor κB (NF-κB) activation. Thus, SAG, in 
a manner depending on the availability of F-box proteins, 
demonstrated early-stage suppression of tumor forma-
tion by promoting c-Jun degradation, thereby inhibiting 
AP-1, and later-stage enhancement of tumor growth, by 
promoting inhibitor of κBα degradation to activate NF-κB 
and inhibit apoptosis.
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(Cooper et al., 2003). In contrast, c-Fos–defi  cient mice are re-
sistant to the malignant progression of skin tumors (Saez et al., 
1995). Suppression of  DMBA/TPA-induced tumor formation 
in manganese superoxide dismutase–overexpressing transgenic 
mice is also associated with modulation of AP-1 signaling (Zhao 
et al., 2001). Thus, AP-1 activation is required for both DMBA/
TPA- and UV-induced skin carcinogenesis.
Sensitive to apoptosis gene (SAG) was initially cloned as 
a redox-inducible gene that encodes an evolutionarily conserved 
really interesting new gene (RING) fi  nger protein (Duan et al., 
1999) and was later found to be the second family member of 
regulator of cullins-1 (ROC1)/RING box protein 1 (Duan et al., 
1999; Kamura et al., 1999; Ohta et al., 1999; Tan et al., 1999; 
Swaroop et al., 2000), the RING component of the Skp1-cullin1–
F-box protein (SCF) E3 ubiquitin ligases that promotes ubi-
q  uitination and degradation of a variety of protein substrates 
(Nakayama and Nakayama, 2006). SAG/ROC/Rbx and cullins 
form the core ubiquitin ligase, whereas the F-box proteins de-
termine its specifi  city by recognizing the substrates (Nakayama 
and Nakayama, 2006). We have recently established an auto-
feedback loop in which SAG is a direct transcriptional target 
of AP-1. Upon induction by AP-1, SAG promotes ubiquitina-
tion and degradation of c-Jun to inhibit AP-1 activity and AP-1–
induced neoplastic transformation in a mouse epidermal cell 
model (Gu et al., 2007). We extended this work to an in vivo 
transgenic model in which SAG expression is driven by a K14 
promoter, and we report that SAG, upon targeted expression in 
the epidermis where an F-box protein (Fbw-7) is expressed, re-
duces TPA-induced c-Jun levels, inhibits AP-1 activity, cell prolif-
eration, and eventually DMBA/TPA-induced skin carcinogenesis. 
However, SAG expression in tumor tissues, where another 
F-box protein, β-transducin repeat-containing protein 1 (β-TrCP1), 
is overexpressed, reduces inhibitor of κBα (IκBα) levels and 
activates nuclear factor κB (NF-κB), resulting in apoptosis 
inhibition and enlarged tumor size. Thus, it appears that SAG 
inhibits tumor formation at the early stage by targeting c-Jun/
AP-1 and promotes tumor growth at the later stage by target-
ing IκBα/NF-κB in a manner dependent on the availability of 
F-box proteins.
Results
Generation of K14-SAG transgenic 
mice with SAG transgenic expression 
in the epidermis
We have recently shown that SAG is a novel AP-1 target and 
that, upon induction, SAG inhibits AP-1 activity and AP-1–
  induced neoplastic transformation by promoting c-Jun ubiquiti-
nation and degradation in cultured cells (Gu et al., 2007). 
Because AP-1/c-Jun is actively involved in promoting skin car-
cinogenesis induced by DMBA/TPA (Saez et al., 1995; Young 
et al., 1999), we tested our hypothesis that SAG would act as 
an inhibitor of skin carcinogenesis. A SAG transgenic construct, 
which, driven by the K14 promoter, targets gene expression 
mainly to the epidermis (Vassar and Fuchs, 1991; Young et al., 
1999), was made (Fig. 1 A) and used to generate the K14-SAG 
transgenic lines in the mouse FVB/N strain that is sensitive to 
DMBA/TPA carcinogenesis (Hennings et al., 1993). Out of a 
total of 106 mice produced, after three consecutive microinjec-
tions of K14-SAG transgenic construct into FVB/N one-cell 
embryos, we identifi  ed 13 K14-SAG transgenic mice via PCR 
genotyping (not depicted). These positive mice were followed 
up for the potential expression of the SAG transgene by RT-
PCR. Expression of trans-SAG mRNA was detected and con-
fi  rmed with sequencing (not depicted). To determine the gene 
copy number, Southern blot analysis was performed in each 
transgenic line. Two lines, 345 and 710, which contained intact 
transgene in a single insertion site with transgene copy numbers 
of  20 and 30, respectively, were identifi  ed (not depicted) and 
chosen for Northern analysis for mRNA expression. As shown 
in Fig. 1 B, compared with nontransgenic lines, which expressed 
a low endogenous level of SAG mRNA, both lines had increased 
levels of SAG mRNA, with a higher level seen in the 710 line, 
refl  ecting a good correlation between transgene copy numbers 
and SAG mRNA levels. Western blot analysis of epidermal 
skin tissues also showed a copy number–dependent increase 
of FLAG-tagged transgenic SAG protein, with a level two- to 
threefold higher than that of the endogenous SAG (Fig. 1 C, 
FLAG-SAG and Endo-SAG). These two transgenic lines, 345 
and 710, with different levels of SAG transgenic expression, 
were chosen for a two-stage DMBA/TPA carcinogenesis study.
Figure 1.  Generation of SAG transgenic mice and reduction of TPA-
  induced c-Jun levels by SAG expression. (A) Map of K14-SAG transgenic 
construct: a 375-bp cDNA fragment encoding N-terminal FLAG-tagged 
human SAG was subcloned into an expression vector driven by a K14 
promoter. K14NC-polyA is a K14 3′-noncoding region with a poly A tail; 
pGem32 is a plasmid cloning vector. (B and C) Transgenic SAG expres-
sion: two transgenic lines, 345 and 710, were selected, and expression 
of exogenous SAG was conﬁ  rmed by Northern (B) and Western blot (C). 
(D) SAG expression in primary keratinocytes inhibits TPA-induced c-Jun accu-
mulation: Primary cultures were prepared from SAG-Tg(+) and SAG-Tg(−) 
mice and were subjected to TPA treatment (20 ng/ml) for 4 h, followed by 
Western analysis for c-Jun, SAG, and β-actin. The fold change was calcu-
lated after densitometry quantiﬁ  cation with β-actin normalization, setting 
the DMSO control value as one.SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1011
Transgenic SAG expression reduced 
TPA-induced c-Jun levels in primary 
keratinocytes and in mouse epidermis
Our previous work in cultured JB6 epidermal cells has shown 
that SAG inhibits TPA-mediated c-Jun induction by promoting 
c-Jun ubiquitination and degradation (Gu et al., 2007). We extended 
this observation to primary keratinocytes isolated from several 
1- to 2-d-old postnatal pups from SAG transgenic (SAG-Tg) 
lines 345 and 710, as well as control nontransgenic littermates. 
Two pairs of primary keratinocytes were either treated with 
DMSO vehicle control or TPA for 4 h. As shown in Fig. 1 D, 
TPA treatment induced c-Jun expression up to 8- to 10-fold in 
keratinocytes from nontransgenic littermates, whereas the same 
treatment caused only a three- to fourfold c-Jun induction in ker-
atinocytes from SAG transgenic lines (Fig. 1 D, top). Expression 
of transgenic SAG was readily detectable in cells from trans-
genic lines, but not from the controls (Fig. 1 D, middle). The 
results demonstrated that SAG transgenic expression inhibits 
TPA-induced c-Jun accumulation. We further confi  rmed this by 
in situ immunohistochemical (IHC) analysis. As shown in Fig. 
2 A, c-Jun was not detectable in the epidermal layer of acetone-
treated mouse skin (top left). TPA application induced strong c-Jun 
nuclear staining in the majority of epidermal cells in SAG-
Tg(−) mice (Fig. 2 A, middle, inset for higher magnifi  cation). 
In SAG-Tg(+) mice, both the number of cells with c-Jun nu-
clear staining and the staining intensity in c-Jun–positive cells 
were reduced (Fig. 2 A, bottom, arrows in inset for c-Jun–negative 
staining cells). No difference in epidermal staining of two con-
trol proteins, c-Fos and p53, was observed between the two lines. 
The c-Fos (Fig. 2 A, middle column) is a strong TPA-inducible 
protein, known to be degraded by UBR1 E3 ligase (Sasaki et al., 
2006), whereas p53 (right column), a weak TPA responder, is 
mainly degraded by Mdm2 E3 ubiquitin ligase (Haupt et al., 
1997). To further demonstrate the effect of SAG transgenic 
expression on c-Jun levels induced by TPA in situ, two consecu-
tive sections in the same areas of mouse skin tissues from 
SAG-Tg(+) and SAG-Tg(−) mice were prepared, respectively, 
with one section stained for FLAG-SAG transgenic expression 
(Fig. 2 B, top) and the other for c-Jun expression (bottom). 
An inverse relationship between SAG transgenic expression 
(detected by anti-FLAG antibody) and c-Jun induction by TPA 
was clearly shown. Thus, SAG, upon ectopic expression, re-
duced TPA-induced c-Jun levels both in primary cultures and 
in mouse skin in vivo. It is noteworthy that the epidermal lay-
ers were thicker in SAG-Tg(−) mice than that in SAG-Tg(+) 
mice (see below).
Transgenic SAG expression reduced TPA-
induced AP-1 binding and transactivation 
in mouse skin tissues
We next determined whether expression of the SAG transgene 
inhibited AP-1 binding and transactivation as a result of c-Jun 
ubiquitination and degradation in in vivo mouse skin tissues 
collected from SAG-Tg(+) mice and their negative littermates, 
SAG-Tg(−). As shown in Fig. 3 A, application of acetone sol-
vent control did not induce any AP-1 DNA binding activity, re-
gardless of SAG transgenic expression (lanes 1–4). However, 
application of TPA twice a week for 4 wk produced substantial 
induction of AP-1 binding in three out of three SAG-Tg(−) 
lines tested (Fig. 3 A, lanes 5–10). Signifi  cantly, SAG trans-
genic expression caused a remarkable reduction of TPA-induced 
AP-1 binding in three out of three SAG-Tg(+) mice (Fig. 3 A, 
lanes 12–18). This dramatic difference in AP-1 binding was 
not due to load discrepancy, as demonstrated by similar levels 
of nuclear histone H2A among all eight samples (Fig. 3 B). 
Furthermore, because AP-1 binding can be supershifted by c-Jun 
antibody (Fig. 3 A, lanes 6, 8, 10, 13, 15, and 17) and com-
pletely blocked by 50× cold oligonuclotide (lanes 11 and 18), 
it was concluded that the AP-1 complex contained c-Jun and the 
binding was specifi  c. Thus, short term TPA application caused 
substantial AP-1 activation, which was remarkably inhibited by 
SAG transgenic expression.
To further confi  rm whether reduced AP-1 binding can be 
correlated with reduced AP-1 transactivation in vivo, we crossed 
AP-1 luciferase reporter mice (Cooper et al., 2003) with SAG-
Tg(+) mice to generate mice that are heterozygous for AP-1–Luc 
reporter in SAG-Tg(+) or SAG-Tg(−) background, respectively. 
The AP-1 activity, as refl  ected by luciferase light units, was sig-
nifi  cantly induced in ear-punched tissues after TPA application. 
SAG transgenic expression signifi  cantly reduced this AP-1 
activity (Fig. 3 C, P < 0.01). Collectively, it is clearly demon-
strated in both in vitro and in vivo settings that SAG, upon 
transgenic expression, signifi  cantly reduced TPA-induced AP-1 
activities (both DNA binding and transactivation) by reducing 
TPA-induced c-Jun accumulation.
SAG transgenic expression reduced 
TPA-induced proliferation in mouse skin
It is well established that, at the early stage of DMBA/TPA 
carcinogenesis, TPA induces hyper-proliferation of the epi-
dermis (DiGiovanni et al., 1980), likely through AP-1 activation. 
We therefore determined that SAG transgenic expression, 
which inhibits AP-1 activity, would block TPA-induced hyper-
proliferation with two independent assays. The fi  rst assay 
was hematoxylin and eosin (H&E) staining, followed by mea-
surement of the thickness of the epidermal layer. Representative 
fi  gures, shown in Fig. 4 A as well as Fig. 2, clearly demonstrate 
that SAG transgenic expression remarkably reduces the thick-
ness of the epidermis. The difference is statistically signifi  cant 
(P < 0.01). The second assay was the BrdU incorporation assay, 
which measures cells with active DNA synthesis. As shown in 
Fig. 4 B, BrdU-labeled cells were mainly localized in the basal 
cell layer. The number of these positive cells was signifi  cantly 
reduced upon SAG transgenic expression (P < 0.01). To further 
demonstrate the effect of SAG transgenic expression on cell 
proliferation in situ, two consecutive sections in the same areas 
of skin tissues from SAG-Tg(+) and SAG-Tg(−) mice were 
prepared, respectively, with one section stained for FLAG-SAG 
transgenic expression (Fig. 4 C, top) and the other for BrdU 
staining (bottom). An inverse relationship between SAG trans-
genic expression and the number of BrdU-positive cells was 
clearly shown. Thus, it appears  that SAG transgenic expression 
reduces the thickness of the epidermis by inhibiting the prolif-
eration of epidermal cells, likely through SAG-induced c-Jun JCB • VOLUME 178 • NUMBER 6 • 2007  1012
reduction and AP-1 inactivation at the early stage of DMBA/
TPA carcinogenesis.
Finally, we determined if SAG transgenic expression alters 
the differentiation pattern of the epidermal cells in response to 
TPA treatment by IHC staining of keratin-5, -6, and -10, three 
commonly used skin differentiation markers (Fuchs and Green, 
1980; Fuchs, 1988). Whereas there is no difference in keratin-5 
and -6 staining in the skin epidermal layers between TPA-
treated SAG-Tg(−) and SAG-Tg(+) mice (unpublished data), 
keratin-10 staining does reveal some differences. Several layers 
(≥2) of keratin-10–negative basal cells were readily detected in 
some areas of the skin from SAG-Tg(−) mice, whereas in 
SAG-Tg(+) mice, keratin-10–negative cells were essentially 
restricted to the single basal cell layer (Fig. 4 D, brackets). 
Figure 2.  SAG transgenic expression reduces c-Jun staining in epidermal cells. Mouse skin tissues after 1× DMBA and 8× TPA applications from SAG-
Tg(−) and SAG-Tg(+) mice (710 line) were subjected to IHC staining using antibodies against c-Jun, c-Fos, p53 (A), and c-Jun and FLAG-tag (B) for SAG 
transgenic expression.SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1013
Moreover, a small subset of basal cells in SAG-Tg(+) mice 
appeared to express keratin-10 precociously. These results sug-
gest that SAG transgenic expression alters the inhibitory effects 
of TPA on expression of spinous cell differentiation markers 
(Toftgard et al., 1985).
SAG transgenic expression delayed 
the latent period of tumor formation, 
reduced the number of tumors per mouse, 
and increased mean tumor size, but had 
no substantial effect on papilloma-to-
carcinoma conversion
Two independent SAG transgenic lines, 345 and 710, with dif-
ferent levels of SAG transgenic expression, along with SAG-
Tg(−) littermates, were used to determine the effect of SAG 
expression and SAG dosage on tumor formation during DMBA/
TPA two-stage carcinogenesis. A single application of DMBA 
(100 nmol/0.2 ml acetone) as initiator was given, followed by 
TPA (5 nmol/0.2 ml acetone, twice a week) promotion for 20 wk. 
As shown in Fig. 5, FVB/N mice are quite sensitive to the 
DMBA/TPA two-stage carcinogenesis protocol, and papillomas 
started to appear after 4–6 wk of TPA promotion in both groups 
(top). It should be noted that almost 95% of nontransgenic 345 
mice developed papillomas after 9 wk of TPA application, 
whereas only 40% of nontransgenic 710 mice developed papil-
lomas (Fig. 5, top). This apparent discrepancy of incidence in 
control mice is likely caused by the use of TPA from two differ-
ent vendors (TPA from Sigma-Aldrich was used for the 345 
line, whereas TPA from Qbiogene was applied to the 710 line). 
Nevertheless, the percentage of mice with one or more papil-
lomas was lower in SAG-Tg(+) mice than that in SAG-Tg(−) 
littermates throughout the promotion period (Fig. 5, top). Statis-
tical analysis revealed a signifi  cant difference between the SAG-
Tg(+) and SAG-Tg(−) mice in the greater SAG-expressing 
710 line (P < 0.05), but not in the lower SAG-expressing 345 
line (P > 0.05), suggesting a SAG dosage effect. Remarkably, 
the mean number of papillomas per mouse was signifi  cantly 
lower in both SAG-Tg(+) lines than that in SAG-Tg(−) litter-
mates (P < 0.0001; Fig. 5, middle). These data clearly demon-
strate that SAG transgenic expression inhibits skin papilloma 
development induced by DMBA/TPA. Interestingly, when mean 
tumor size was measured, the papillomas in both SAG-Tg(+) 
lines were statistically bigger than those of their transgenic neg-
ative littermates (Fig. 5, bottom; P = 0.0026 and P = 0.0043 for 
the 710 and 345 lines, respectively). The observed decrease of 
mean tumor size in the 710 line between weeks 13.5 and 14.5, 
and weeks 18.5 and 19.5 (Fig. 5, bottom right), was caused by 
the death of two mice bearing large tumors. These results dem-
onstrate that SAG transgenic expression promoted tumor growth 
after tumor formation.
We also measured the rate of conversion from papilloma 
to carcinoma in the 345 line after 20 wk of TPA promotion and 
in the 710 line after 29 wk of TPA promotion (9 wk after termi-
nation of 20 wk of TPA application). The data are  summarized 
in Table I. In the 345 line, the conversion rate was very low 
(<10%), with no statistical difference between SAG-Tg(+) and 
Figure 3.  Reduction of TPA-induced AP-1 
activity by SAG transgenic expression: SAG 
transgenic expression reduces activity of AP-1. 
(A) Nuclear extracts were prepared from mouse 
skin tissues of three SAG-Tg(−) and three SAG-
Tg(+) mice (710 line) after 1× DMBA and 8× 
TPA applications, and subjected to gel retarda-
tion assay for AP-1–speciﬁ  c binding as well as 
Western blotting of histone H2A for equal load-
ing of nuclear proteins (B). The brackets in A in-
dicate that the nuclear extracts in these lanes 
were from the same sample with or without the 
addition of the c-Jun antibody or cold competitive 
oligonucleotide (50×), as indicated. (C) SAG 
transgenic expression reduces TPA-induced AP-1 
activity in vivo: SAG-Tg(+) mice (710 line) were 
crossed with AP-1–Luc reporter mice and off-
spring were genotyped. The mice that were 
heterozygous for AP-1–Luc reporter and SAG-
Tg(+) (n = 7) or SAG-Tg(−) (n = 10) were 
used. Each mouse was painted with acetone 
control on the left ear and TPA on the right ear. 
Ear samples were collected 24 h after TPA ap-
plication and subjected to luciferase assay. Fold 
induction was calculated by setting the lucifer-
ase light unit from acetone treated ear as one. 
*, P < 0.01. JCB • VOLUME 178 • NUMBER 6 • 2007  1014
Figure 4.  Inhibition of TPA-induced proliferation of skin epidermis by SAG transgenic expression. Skin thickness measurement (A), BrdU incorporation 
assay (B), and inverse relationship between SAG transgenic expression and the number of BrdU-positive cells (C) are shown. SAG-Tg(−) and SAG-Tg(+) mice 
(710 line) after 1× DMBA and 8× TPA applications were given an i.p. injection of the BrdU labeling reagent 2 h before being killed. The skin tissues were 
collected and subjected to H&E staining (A), BrdU staining (B), or FLAG-tag and BrdU staining (C). A representative area was shown. The thickness of epi-
dermal layer was measured under microscope and expressed in millimeters after 400× magniﬁ  cation (mm/400) as described in Materials and methods. The 
number of BrdU-positive cells in a total of 1,000 epidermal cells was counted as described in Materials and methods. Error bars represent mean ± SD from SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1015
SAG-Tg(−) mice. In the 710 line, the conversion rate was much 
higher, reaching 25%, as expected, caused by the additional 9 wk 
of tumor growth after TPA promotion. But again, no statistical 
difference (P > 0.05) was observed between the SAG transgenic 
lines and their negative littermates, although invasive squamous 
carcinomas were more frequently seen in SAG-Tg(+) mice. 
Thus, SAG transgenic expression has no signifi  cant role in pro-
moting papilloma-to-carcinoma conversion.
SAG transgenic expression promoted 
tumor growth by apoptosis inhibition via 
NF-𝗋B activation
The increased tumor size seen in SAG-Tg(+) lines could result 
from either increased proliferation or decreased apoptosis in the 
papillomas. To determine which, we fi  rst assayed BrdU incor-
poration in papillomas derived from SAG-Tg(−) and SAG-Tg(+) 
mice. As shown in Fig. 6 A (a–e), taken from two represen tative 
areas of two independent tumors, many BrdU-positive cells were 
seen across the tumor tissues, indicating that the rate of BrdU 
incorporation was much higher in tumors than in skin tissues 
after just a few TPA exposures (Fig. 4 B). However, no differ-
ence was found between the two groups, indicating that SAG 
transgenic expression had no effect on  DNA synthesis, thus ex-
cluding the potential difference in the rate of cell proliferation. 
We next determined the rate of apoptosis using the TUNEL 
assay, because we have previously shown that SAG, upon over-
expression, protects cells or tissues from apoptosis (Duan et al., 
1999; Yang et al., 2001; Chanalaris et al., 2003). In two repre-
sentative areas of two independent tumors shown in Fig. 6 B, 
TUNEL-positive cells were either localized at the junction of 
Figure 5.  Inhibition of tumor formation, but promotion of tumor growth by SAG transgenic expression. A standard DMBA/TPA two-stage carcinogenesis 
protocol was used in two SAG-Tg(+) lines, 345 (n = 13 for SAG-Tg(+) and n = 15 for SAG-Tg(−)) and 710 (n = 17 for both SAG-Tg(+) and SAG-Tg(−)). 
The number of papillomas detected by palpation and the size of the tumor detected by a caliper in each group were recorded twice a week after their ap-
pearance and plotted. SAG transgenic expression prolonged the latent period for tumor formation as measured by percentage of mice with papillomas ver-
sus time (top). SAG transgenic expression inhibited tumor formation as measured by the mean number of tumors in each tumor-bearing mouse versus time 
(middle), and SAG transgenic expression promoted tumor growth as measured by the mean size of tumors in all tumor-bearing mice versus time (bottom).
two to three mice with 16 measurements per mouse (A) or from three mice with two random areas per mouse counted (B). *, P < 0.01. (D) SAG transgenic 
expression altered the keratin-10 staining: mouse skin tissues after 1× DMBA and 8× TPA applications from SAG-Tg(−) and SAG-Tg(+) mice (710 line) were 
subjected to IHC staining using the antibody for keratin-10, as indicated.JCB • VOLUME 178 • NUMBER 6 • 2007  1016
living and keratinized cells (Fig. 6 B, a and b) or scattered across 
the tumor tissues (Fig. 6 B, c and d). In either case, the number 
of TUNEL-positive cells was remarkably reduced in papillomas 
derived from the SAG-Tg(+) mice (Fig. 6 B, b and d), com-
pared with those from the SAG-Tg(−) mice (Fig. 6 B, a and c). 
The difference was statistically signifi  cant (Fig. 6 B, e; P < 0.01). 
Similar results were observed using IHC staining for cleaved 
active caspase-3 (Fig. 6 C). Cells with active caspase-3 staining, 
indicative of apoptosis, were either clustered in one region (Fig. 
6 C, a and b) or scattered across tumor tissues (Fig. 6 C, c and d). 
More active caspase-3 staining was observed in tumors derived 
from SAG-Tg(−) mice than in those derived from SAG-Tg(+) 
mice (Fig. 6 C, e; P < 0.01). Thus, increased tumor size seen in 
SAG-Tg(+) mice was not caused by accelerated proliferation, 
but rather by reduced apoptosis.
To determine the potential mechanism by which SAG ex-
pression inhibited apoptosis, we measured p65 nuclear trans-
location and NF-κB activation in papillomas derived from 
SAG-Tg(−) and SAG-Tg(+) mice. NF-κB is a well-known cel-
lular survival factor that, upon activation, protects cancer cells 
from apoptosis (Karin, 2006). NF-κB (a heterodimer of p50/
p65) is activated after translocation from cytoplasm to the nu-
cleus after the degradation of IκB, a substrate of SCF–β-TrCP1 
E3 ubiquitin ligase (Yaron et al., 1998). It has been previously 
shown that constitutive expression of a SAG phosphoactive 
form leads to reduction of IκBα levels (Kim et al., 2003), sug-
gesting that SAG could activate NF-κB by promoting IκBα 
degradation. As shown in Fig. 7 A, IHC staining revealed that, 
although the cell boundary is less evident because of the nature 
of p65 immunostaining, p65 was clearly localized outside of the 
nucleus but inside the cytoplasm of the majority of tumor cells 
derived from SAG-Tg(−) mice (Fig. 7 A, a, arrows in inset for 
tumor cells without nuclear staining). In contrast, p65 was 
translocated to the nucleus, with strong nuclear staining in the 
majority of tumor cells from SAG-Tg(+) mice (Fig. 7 A, b, 
arrows in inset for positive staining cells). Thus, SAG trans-
genic expression promotes p65 translocation from the cytoplasm 
to the nucleus.
We next applied a DNA-binding gel retardation assay to 
determine if NF-κB is activated. HeLa cells, treated with TNF-α, 
were used as positive controls (Fig. 7 B, lanes 1–4). Consistent 
with the data concerning p65 localization, although mainly 
localized in the cytoplasm, NF-κB was inactive and failed to 
bind to its consensus DNA sequence in fi  ve out of fi  ve papil-
lomas harvested from fi  ve individual SAG-Tg(−) mice (Fig. 7 B, 
lanes 5–10). In contrast, nuclear localized NF-κB was active 
and bound to its consensus DNA sequence in four out of four 
papillomas harvested from four individual SAG-Tg(+) mice 
(Fig. 7 B, lanes 11–18). Because the NF-κB DNA binding can 
be supershifted by the p65 antibody (Fig. 7 B, lanes 3, 14, and 17) 
and blocked by specifi  c cold oligonucleotides (Fig. 7 B, lanes 4, 
15, and 18), we concluded that it is specifi  c. To determine the 
potential changes in AP-1 activity in these tumors, the same 
samples were subjected to an AP-1 binding assay (Fig. 7 C). 
Compared with the skin tissue exposed to TPA (Fig. 7 C, lanes 
1–3), the AP-1 binding activity in these tumor samples was very 
low (Fig. 7 C, lanes 4–16) and varied between tumors. However, 
no difference was observed between SAG-Tg(−) (Fig. 7 C, 
lanes 4–10) and SAG-Tg(+) (lanes 11–16) mice, indicating that, 
in tumor tissues, AP-1 is largely inactive, regardless of SAG 
transgenic expression. Collectively, we concluded that the in-
creased tumor size seen in SAG-Tg(+) mice was caused by 
reduced apoptosis, resulting at least in part from SAG-mediated 
p65 nuclear translocation, followed by NF-κB activation.
F-box proteins–dependent SAG regulation 
of AP-1 and NF-𝗋B
SAG is a RING component of the SCF E3 ubiquitin ligases, 
whose substrate-degrading activity requires F-box proteins that 
recognize substrates (Zheng et al., 2002). It is well established 
that the F-box proteins that recognize c-Jun and IκBα are 
Fbw7/Cdc4 (Nateri et al., 2004; Wei et al., 2005) and β-TrCP1 
(Yaron et al., 1998), respectively. We therefore determined the 
levels of c-Jun, IκBα, Fbw7, and β-TrCP1 during DMBA/TPA-
induced skin carcinogenesis. Consistent with results in primary 
keratinocytes (Fig. 1 D), the c-Jun levels were very low or un-
detectable in mouse skin tissues treated with acetone solvent 
(Fig. 8 A, top, lanes 1 and 2), and dramatically induced after 
TPA treatment in SAG-Tg(−) mice (Fig. 8 A, top, lanes 3 and 4). 
TPA-mediated c-Jun induction was substantially reduced in 
SAG-Tg(+) mice (Fig. 8 A, lanes 5 and 6). The c-Jun levels 
were, however, very low in tumor tissues regardless of SAG 
transgenic expression (Fig. 8 A, lanes 7–9). In contrast, the lev-
els of IκBα (Fig. 8 A, second panel) were quite high in skin 
tissues as well as tumor tissues from SAG-Tg(−) mice (lanes 
1–7), but remarkably reduced in tumor tissues from SAG-
Tg(+) mice (lanes 8 and 9). The levels of β-TrCP1 (Fig. 8 A, 
third panel) were very low or undetectable in skin tissues (lanes 
1–6), but remarkably increased in tumor tissues, regardless of 
SAG transgenic expression (lanes 7–9). Because the Fbw7 
levels were found to be very low in the cells, and could only 
be detected by immunoprecipitation-coupled Western blotting 
Table I. Papilloma-to-carcinoma conversion
345 line (20 wk after promotion) 710 line (29 wk after promotion)
Group Papillomas (%) Papillomas with early 
local invasion (%)
Invasive SSC or spindle 
cell carcinoma (%)
Papillomas (%) Papillomas with early 
local invasion (%)
Invasive SSC or spindle 
cell carcinoma (%)
SAG-Tg(−) 50 (92.6) 2 (3.7) 2 (3.7)
2 FS
39 (69.6) 6 (10.7) 11 (19.6)
2 FS
SAG-Tg(+) 46 (85.2) 3 (5.6) 5 (9.3)
1 FS
25 (58.1) 7 (16.3) 11 (25.6)
1 FS
FS, ﬁ  broblast sarcoma; SCC, squamous cell carcinoma.SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1017
analysis (Strohmaier et al., 2001), we performed the analysis 
using the same Fbw7 antibody (Strohmaier et al., 2001). Fbw7 
was only detected in skin tissues (Fig. 8 B, lanes 1–4), but not 
in tumor tissues (Fig. 8 B, lanes 5–8), regardless of SAG trans-
genic expression.
We further measured the expression of c-Jun, IκBα, 
β-TrCP1, and transgenic SAG in four independent tumors from 
four individual SAG-Tg(−) or SAG-Tg(+) mice, respectively 
(Fig. 8 C). Again, very low levels of c-Jun (Fig. 8 C, top) and 
relatively high levels of β-TrCP1 (third panel) were detected, 
Figure 6.  Apoptosis inhibition by SAG transgenic expression. SAG-Tg(−) and SAG-Tg(+) (710 line) mice at the end of 20 wk of TPA promotion were 
given an i.p. injection of the BrdU-labeling reagent 2 h before being killed. Tumors with the size of 5–7 mm in diameter were collected and subjected to 
BrdU assay (A, positive cells shown in blue); TUNEL assay (B, propidium iodide staining for nucleus shown in red, TUNNEL-positive nuclei shown in 
green); or active caspase-3 staining (C, positive cells shown in brown). Two representative areas from two individual tumors derived from two different 
mice, respectively, are shown (a–d). The number of positive cells out of a total of 1,000 tumor cells in each area from 10 tumors harvested from six indi-
vidual mice in each line was counted, and data were summarized and presented as mean ± SD in bar graphs with error bars and analyzed by Student’s 
t test (e). *, P < 0.01. JCB • VOLUME 178 • NUMBER 6 • 2007  1018
regardless of SAG transgenic expression, which was only shown 
in SAG-Tg(+) tumors (fourth panel). In contrast, the level of 
IκBα (Fig. 8 C, second panel) was quite high in tumors from 
SAG-Tg(−) mice, but dramatically reduced in tumors from 
SAG-Tg(+) mice, strongly suggesting that SAG transgenic ex-
pression promotes IκBα degradation when β-TrCP1 levels are 
high enough. Finally, we measured the expression of other com-
ponents of SCF E3 ubiquitin ligase, including Cul-1, Skp1, and 
ROC1, a SAG family member. They were all expressed consti-
tutively, with no difference between mouse skin tissues and 
tumors (Fig. 8 D), indicating that they are unlikely to be critical 
in regulation of skin carcinogenesis. Collectively, these results 
showed that SAG regulation of AP-1 and NF-κB activity is 
dependent of the levels of F-box proteins Fbw7 and β-TrCP1 
with SAG as a rate-limiting factor.
Discussion
The SCF E3 ubiquitin ligases comprise the largest family of 
E3 ubiquitin ligases that ubiquitinate a variety of regulatory 
proteins for 26S proteasome degradation (Nakayama and 
Nakayama, 2006). The core SCF E3 ubiquitin ligase is a complex 
of ROC1–cullin or SAG–cullin that recruits E2, whereas the 
substrate specifi  city of the SCF complex is determined by the 
Figure 7.  NF-𝗋B activation by SAG transgenic expression. Subcellular localization of p65 (A) was detected using IHC analysis in SAG-Tg(−) and SAG-
Tg(+) tumors, with arrows in insets showing negative or positive cells for p65 nuclear staining. Activation of NF-κB (B), but not AP-1 (C), in tumors derived 
from SAG-Tg(+) mice: individual tumors from different SAG-Tg(−) or SAG-Tg(+) mice, respectively, were collected for gel retardation assay for NF-κB bind-
ing (B, lanes 5–9, ﬁ  ve tumors from SAG-Tg(−) mice; lanes 11–13 and 16, four tumors from SAG-Tg(+) mice) or AP-1 binding (C, lanes 4–8, the same 
tumors as B in lanes 5–9; lanes 11–14, the same tumors as B in lanes 11–13 and16). HeLa cells after TNF-α stimulation (B, lanes 1–4) and a skin tissue 
sampled from SAG-Tg(−) mice after 8× TPA exposures (C, lanes 1–3) were used as positive controls. The brackets indicate that the nuclear extracts in these 
lanes were from the same sample without or with the addition of the antibody or cold competitive oligo, as indicated. White lines indicate that intervening 
lanes have been spliced out.SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1019
F-box proteins that bind to Skp1 and cullin through their F-box 
domain, and to substrates through their WD40 or LRR domains 
(Zheng et al., 2002). The SCF E3 ligase promotes ubiquitina-
tion and degradation of c-Jun through the F-box protein Fbw7/
Cdc4 (Mao et al., 2004; Nateri et al., 2004; Wei et al., 2005), 
whereas the SCF E3 ligase promotes ubiquitination and degra-
dation of IκB through the F-box protein β-TrCP1 (Yaron et al., 
1998), which leads to NF-κB activation and apoptosis protection. 
Thus, SCF E3 ubiquitin ligases regulate cell cycle progression 
and apoptosis through timely ubiquitination and degradation of 
their regulators (Nakayama and Nakayama, 2006).
SAG is a stress-responsive protein and is inducible by a 
variety of stimuli, including hypoxia, metal ions, and the tumor 
promoter TPA (Duan et al., 1999; Chanalaris et al., 2003; 
Gu et al., 2007). Upon induction or overexpression, SAG acts as a 
survival protein to protect cells and normal tissues from apoptosis 
in several in vitro and in vivo models (Duan et al., 1999; Yang et al., 
2001; Chanalaris et al., 2003). We have recently found that, as a 
RING component of SCF E3 ubiquitin ligases, SAG promotes 
ubiquitination and degradation of c-Jun, an essential member of 
the AP-1 transcription factor. As a consequence, TPA-induced 
and AP-1-mediated neoplastic transformation in the JB6 epider-
mal cell model is inhibited upon SAG expression or enhanced 
upon SAG siRNA silencing (Gu et al., 2007). We demonstrated, 
using an in vivo transgenic mouse model, that SAG, upon tar-
geted expression in mouse skin epidermal cells driven by K14 
promoter, inhibited DMBA/TPA-induced skin carcinogenesis, 
as indicated by a prolonged latent period and a reduced tumor 
frequency. This is very likely attributable to inhibition of TPA-
induced c-Jun accumulation, followed by inactivation of AP-1 
activity at the early stage of carcinogenesis. The fact that targeted 
SAG transgenic expression is two- to threefold higher than that 
of endogenous SAG suggested that SAG is a rate-limiting factor 
for the modulation of activity of SCF E3 ubiquitin ligases in 
mouse skin or tumors induced by DMBA/TPA. Indeed, our data 
showed that the two- to threefold increase in SAG caused a two- 
to threefold reduction in TPA-induced c-Jun levels and TPA-
induced AP-1 binding and transactivation, which also correlated 
with an approximately twofold reduction in papilloma formation. 
Two previous studies using transgenic mice expressing TAM67, 
a dominant-negative form of c-Jun, also showed a good correla-
tion between inhibition of AP-1 and inhibition of skin carcino-
genesis. It was observed that a twofold decrease in UVB-induced 
AP-1 activation in the epidermis of TAM67 transgenic SKH-1 
mice correlated with a twofold reduction in the number of skin 
tumors induced by UVB (Cooper et al., 2003), whereas a 4.5-
fold reduction of TPA-induced AP-1 activation correlated well 
with a fi  vefold inhibition of papilloma formation (Young et al., 
1999). Collectively, it appears that blockage of c-Jun/AP-1 activ-
ity has a dose-dependent effect on skin carcinogenesis.
It appeared paradoxical that the same SAG protein, upon 
targeted expression, would inhibit tumor formation at the early 
stage, but promote tumor growth at the later stage of carcino-
genesis. This may be explained by differential expression of 
two F-box proteins, Fbw7/Cdc4 and β-TrCP1, during carcino-
genesis. Fbw7/Cdc4 is a p53-dependent, haploinsuffi  cient tumor 
suppressor gene (Mao et al., 2004). Mutational inactivation 
and loss of heterozygosity of Fbw7 is seen in several human 
cancers (Strohmaier et al., 2001; Minella and Clurman, 2005). 
Fbw7 binds to phosphorylated c-Jun and promotes its ubiqui-
tination and subsequent degradation. As a result, SCF
Fbw7 short-
ened the c-Jun protein’s half-life and inhibited AP-1 activity 
and apoptosis. Consistent with this, knock down of Fbw7 ex-
pression via RNAi increased the level of phosphorylated c-Jun, 
followed by enhanced AP-1 activity and apoptosis induction 
(Mao et al., 2004; Nateri et al., 2004; Wei et al., 2005). We show 
in this paper that at the early stage of DMBA/TPA carcinogene-
sis, Fbw7 is expressed and cooperates with rate-limiting SAG 
to promote c-Jun degradation, leading to reduction of AP-1 ac-
tivity (Figs. 3 A and 8 B) and inhibition of proliferation and 
tumorigenesis (Figs. 4 and 5). In the late stage of carcinogenesis, 
Figure 8.  Altered expression of F-box proteins Fbw7 and 𝗃-TrCP1 and 
their substrates, c-Jun and I𝗋B𝗂, during DMBA/TPA skin carcinogenesis. 
Mouse skin tissues or tumors from SAG-Tg(−) and SAG-Tg(+) mice were 
harvested, homogenized, and subjected to Western blotting (A, C, and D) 
using antibodies against c-Jun, β-TrCP1, IκBα, SAG, Cul-1, Skp1, ROC1, 
and β-actin. Tissue lysates from mouse skin tissues or tumors from SAG-
Tg(−) or SAG-Tg(+) mice were subjected to immunoprecipitation, followed 
by Western blotting using Fbw7 antibody (B). JCB • VOLUME 178 • NUMBER 6 • 2007  1020
when tumors are formed, the expression of Fbw7 is down-
regulated and undetectable (Fig. 8 B). Although the mechanism 
is still elusive, our observation of loss of Fbw7 expression dur-
ing skin carcinogenesis suggests that it is a change favored and 
selected for in tumor formation. It appears that the lack of Fbw7 
prevents SAG’s ability to promote c-Jun degradation, leading to 
a similar AP-1 activity (although very low, due to the lack of 
TPA induction) in tumors from SAG-Tg(−) and SAG-Tg(+) 
mice (Fig. 7 C). Furthermore, because AP-1 is not activated in 
the tumors (Fig. 7 C) and c-Jun levels are very low in these 
tumors, regardless of SAG transgenic expression (Fig. 8), our 
model strongly suggests that AP-1 is unlikely to play a consid-
erable role in the growth of DMBA/TPA-induced tumors, al-
though c-Jun/AP-1 has been implicated in apoptosis regulation 
that could infl  uence the tumor growth in many other systems 
(Eferl and Wagner, 2003).
In contrast to Fbw7, β-TrCP1 was found to be over-
expressed in colon cancers with associated activation of both 
β-catenin and NF-κB and inhibition of apoptosis (Ougolkov et al., 
2004). Increased levels of β-TrCP1 were also found in pancreatic 
carcinoma cells, which correlated with constitutive NF-κB acti-
vation and chemoresistance (Muerkoster et al., 2005). Likewise, 
targeting β-TrCP1 via siRNA silencing or overexpression of a 
dominant-negative mutant suppressed growth and survival of 
human breast cancer cells (Tang et al., 2005). Furthermore, mouse 
β-TrCP2 was overexpressed in skin tumors generated by DMBA-
TPA two-stage carcinogenesis, causing a constitutive activation 
of NF-κB through reduction of IκBα (Bhatia et al., 2002). 
  Consistent with this, we found that, regardless of SAG trans-
genic expression, the levels of β-TrCP1 were very low or not 
detectable in mouse skin, but signifi  cantly elevated in tumors 
induced by DMBA/TPA, likely caused by the activation of 
Ras-Raf pathways as a result of DMBA-initiated Ras mutation 
(Balmain and Pragnell, 1983; Liu et al., 2007). However, only 
SAG-overexpressing tumors had reduced IκBα levels and acti-
vated NF-κB activity, suggesting that SAG is a rate-limiting 
factor in SCF–β-TrCP1–mediated IκBα degradation (Figs. 
7 and 8). It is worth noting that NF-κB has been previously shown 
to regulate spontaneous skin carcinogenesis with inconsistent 
results. Upon targeted overexpression by a K5 promoter of a 
superrepressor form of IκBα (leading to continued inactivation 
of NF-κB) in mouse skin, an increased basal rate of apoptosis 
and the spontaneous development of squamous cell carcinomas 
were observed (van Hogerlinden et al., 1999). In contrast, tar-
geted ablation of α-catenin, an adherens junction protein, re-
sulted in NF-κB activation and formation of squamous cell 
carcinoma in the skin (Kobielak and Fuchs, 2006). Neverthe-
less, our results showed that NF-κB was marginally activated at 
the early stage (unpublished data), but signifi  cantly activated in 
tumors from SAG-Tg(+) mice, resulting in apoptosis inhibition 
in the DMBA/TPA two-stage carcinogenesis model.
Based on these observations, we propose a model to elu-
cidate the role of SAG in skin carcinogenesis (Fig. 9). At the 
early stage of carcinogenesis, SAG is induced by carcinogens/
tumor promoters via AP-1 transactivation as a cellular protective 
mechanism (Gu et al., 2007). Upon induction, SAG cooperates 
Figure 9.  The role of SAG in skin carcinogenesis, a model. At the early stage of DMBA/TPA skin carcinogenesis, c-Jun is accumulated and AP-1 is activated 
to promote cell proliferation and tumor formation. SAG, upon induction, recruits Fbw7, a tumor suppressor and an F-box protein that binds to c-Jun, to pro-
mote ubiquitination and degradation of c-Jun to block AP-1 activity, thus inhibiting tumor formation. When a tumor is formed at the later stage, however, 
SAG recruits overexpressed β-TrCP1, an F-box protein that binds to IκBα, to promote ubiquitination and degradation of IκBα, leading to activation of NF-κB, 
inhibition of apoptosis, and enlargement of tumor size. SAG/ROC2 REGULATES SKIN CARCINOGENESIS • GU ET AL. 1021
with the tumor suppressor Fbw7 to promote ubiquitination and 
degradation of c-Jun, thus inactivating AP-1 and inhibiting car-
cinogenesis. At this stage, because the β-TrCP1 level is very 
low, SAG had little, if any, effect on NF-κB. However, at the 
later stage, when tumors are formed, SAG, in the presence of 
overexpressed β-TrCP1, promotes IκBα degradation, leading 
to the activation of NF-κB, inhibition of apoptosis, and enlarge-
ment of tumor size. At this stage, SAG has little, if any, effect on 
AP-1 because TPA is no longer present to induce AP-1 and 
Fbw7 is no longer detectable. Indeed, SAG overexpression was 
detected in a subset of human colon cancers and nonsmall cell 
lung carcinomas and was associated with worse patient prognoses 
(Huang et al., 2001; Sasaki et al., 2001). Thus, SAG targeting 
for induction or inhibition appears to be stage dependent. It might 
be benefi  cial to induce SAG in normal tissues or at the early 
stage of carcinogenesis for cancer prevention and to inhibit SAG 
at the late stage, when tumors have formed, for cancer therapy 
via apoptosis induction (Sun, 2006).
Materials and methods
Generation of SAG transgenic mice and epidermal primary culture
A 375-bp cDNA fragment encoding FLAG-tagged human SAG protein 
with a BamHI site was subcloned into the single BamHI site of the K14/ 
human growth hormone (hGH) expression vector (Vassar and Fuchs, 
1991; Young et al., 1999). The construct was digested with HindIII–KpnI; 
the fragment containing K14-promoter–FLAG-SAG PolyA was excised and 
injected into a FVB/N mouse egg by the Transgenic Core at the University 
of Michigan. The University of Michigan Animal Care and Use Committee 
approved the procedures for the use of laboratory animals. Transgenic 
mice were genotyped by direct PCR using tail biopsy DNA with primers 
FLAG-SAG–Tg01 (5′-C  G  G  G  A  T  C  C  G  C  C  A  C  C  A  T  G  G  A  C  T  A  C  A  A  G  G  A  C  G  A  C-
G  A  T  G  A  C  A  A  G  G  C  C  G  A  C  G  T  G  G  A  A  G  A  C  G  G  A  G  -3′) and hGH-02 (5′-G  G  G-
A  A  T  G  G  T  T  G  G  G  A  A  G  G  C  A  C  T  G  -3′; Young et al., 1999). Primary murine 
skin keratinocytes were isolated from the epidermis of 1- to 2-d-old mice 
(Dlugosz et al., 1995).
Northern, immunoprecipitation, and Western blotting analyses
Analyses were performed as described previously (Gu et al., 2007). The 
antibodies against Fbw7, c-Jun, IκBα, Skp1, cullin-1, and histone H2A 
were obtained from Santa Cruz Biotechnology, Inc. β-TrCP1 from Zymed 
Laboratories, β-actin from Sigma-Aldrich, and SAG and ROC1 as described 
previously (Gu et al., 2007).
IHC
The skin or tumor specimens were excised and ﬁ  xed in 4% PFA-PBS for 3 d 
at 4°C and embedded in parafﬁ  n. 4-μm-thick sections were cut for immuno-
staining with ABC kits (Vector Laboratories). The primary antibodies used 
were against c-Jun, c-Fos, p53 (Santa Cruz Biotechnology, Inc.), FLAG-tag 
(Sigma-Aldrich), cleaved caspase-3 (Cell Signaling Technology), mouse 
keratins-5 and -6 (Covance), and mouse keratin-10 (Lab Vision). Normal 
goat serum was used as a negative control. The papilloma-to-carcinoma 
conversion was determined through histopathological observation after 
H&E staining. Keratin-14 (Vector Laboratories) was stained to show the ori-
gin of the tumor cells. A microscope (BX51; Olympus) with objective lenses 
(UplanFI 40×; Olympus) was used. The experiments were performed at a 
temperature of 25°C. A mounting medium was used for the imaging medium 
(Cytoseal 60; Richard-Allan Scientiﬁ  c). The ﬂ  uorochromes used were green 
ﬂ  uorescence and propidium iodide (For TUNEL assay). A camera (DP70; 
Olympus) and acquisition software (DP70-BSW, version 01.02; Olympus) 
were also used. All images, pictures, and ﬁ  gures were prepared with Illus-
trator CS2 and Photoshop CS2 (Adobe).
Preparation of nuclear extracts and gel retardation assay
Nuclear extracts were prepared from mouse skin and tumors as described 
previously (Zhao et al., 2001; Gu et al., 2007) and subjected to gel retar-
dation assay (Gu et al., 2007), using oligonucleotides containing a typical 
AP-1 binding site, AP-1-01 (5′-C  G  C  T  T  G  A  T  G  A  G  T  C  A  G  CCGGAA-3′), or 
NF-κB site, NFκB-01 (5′-A  G  T  T  G  A  G  G  G  G  A  C  T  T  T  C  C  C  A  G  -3′).
Generation of SAG-AP-luc mice and in vivo AP-1 activity assay
SAG-Tg(+)/710 line mice were crossed with AP-1–luc SKH mice (Cooper 
et al., 2003). The SAG–AP-1–Luc mice were typed by PCR analysis of tail 
DNA. The primers used were Luc-01 (5′-G  C  G  G  A  A  T  A  C  T  T  C  G  A  A  A  T  G  T  C  C  G-
T  T  C  G  G  T  T  G  G  -3′) and Luc-02 (5′-C  C  T  T  A  G  G  T  A  A  C  C  C  A  G  T  A  G  A  T  C  C  A  G  A  G-
G  A  A  T  T  C  -3′). The SAG primers were FLAG-SAG–TG-01 and hGH-02. 
AP-1–Luc activity was measured in a total of 10 AP-1–Luc(+)/SAG(−) mice 
and seven AP-1–Luc(+)/SAG(+) mice. The mice were treated with 50 μl 
of acetone on the left ear and 50 μl TPA (5 nmol) on the right ear. After 24 h, 
three ear punches (per ear) of 3 mm were collected. Tissues were ground 
with a microtube pestle and lysed in 1× passive lysis buffer for 1 h, followed 
by luciferase activity measurement (Gu et al., 2007).
Measurement of skin thickness
After a single application of DMBA followed by eight treatments with TPA, 
three mice from the SAG-Tg(+) (710) line and three of their SAG-Tg(−) lit-
termates were killed 24 h after the last TPA treatment, along with two mice 
in each group treated with acetone controls. Samples were collected and 
4-μm sections were stained with H&E. A total of 16 measurements were 
made for each mouse in a systematic manner under a microscope, starting 
from the top of the basement membrane to the bottom of the strateum corneum. 
The skin thickness from each mouse was then averaged within the group, 
expressed as milimeters after 400× (mm/400), and subjected to Student’s 
t test for statistical difference.
DMBA/TPA two-stage carcinogenesis
SAG-Tg(+) and SAG-Tg(−) mice (for 345 line: K14-SAG, n = 15, and 
control, n = 13; for 710 line: K14-SAG, n = 17, and control, n = 17) at 
7–8 wk of age were used for the DMBA/TPA two-stage carcinogenesis 
protocol. A single dose (100 nmol) of DMBA (Sigma-Aldrich) in 0.2 ml of 
acetone was applied topically to the shaved backs of mice. 2 wk after initi-
ation, TPA (5 nmol; Sigma-Aldrich for 345 line and Qbiogene for 710 line) 
in 0.2 ml of acetone was applied twice weekly to the skin for 20 wk. The 
presence of the tumor and the size of these tumors were measured twice a 
week using a digital caliper (Fisher Scientiﬁ  c).
BrdU incorporation assay
SAG-Tg(+) and SAG-Tg(−) mice were injected i.p. with 2 ml/100g 
(body weight) BrdU-labeling reagent. Mice were killed 2 h later and skin 
tissues or tumors with diameters of 5–7 mm were collected and ﬁ  xed in 4% 
PFA-PBS. The assay was performed with a 5-bromo-2′-deoxy-uridine label-
ing and detection kit II (Roche). Slides were developed with NBT/BCIP 
and counterstained with Eosin (Richard-Allan Scientiﬁ  c). For quantiﬁ  cation 
of BrdU-positive cells in mouse skin, two random areas were selected 
from each mouse (three mice per group), and the number of positive cells 
out of a total of 1,000 epidermal cells was counted. For quantiﬁ  cation 
of BrdU-positive cells in tumors, two random areas were selected from 
each tumor. The number of positive cells out of a total of 1,000 cells was 
counted in each area. Student’s t test was performed to determine the 
statistical difference.
TUNEL assay
Tumors with a size of  5–7 mm in diameter (10 of each from the SAG-
Tg(+) and SAG-Tg(−) mice) were excised and ﬁ  xed in 4% PFA-PBS and 
embedded in parafﬁ  n. 4-μm-thick sections were cut, and deparafﬁ  nized 
slides were used for the TUNEL assay by means of the in situ cell death 
detection kit (Roche). The slides were stained with the TUNEL reaction mixture, 
along with the label solution for the negative control, and counterstained 
with propidium iodide counterstaining solution. The slides were mounted 
and analyzed under a ﬂ  uorescence microscope. For quantiﬁ  cation of TUNEL-
positive cells, two random areas were selected from each tumor. The num-
ber of positive labeling cells (in green) out of a total of 1,000 cells was 
counted in each area. Student’s t test was performed to determine the sta-
tistical differences.
Statistical analysis
Data were analyzed using SAS v9.1 (SAS Institute). All hypotheses were 
tested at the 0.05 signiﬁ  cance level. The volume of each individual tumor 
was recorded from each SAG-Tg(+) or SAG-Tg(−) mouse for a period of 
20 wk of TPA promotion to reﬂ  ect a growth rate of each tumor. Tumor vol-
ume was log transformed, and a random slopes and intercepts model (van 
Leeuwen et al., 1996), implemented in SAS PROC MIXED, was used to 
estimate the growth rate of each tumor and to analyze the effect of SAG-
Tg(+/−). This analysis appropriately considers the clustering of multiple 
tumors with animals. Counts of tumors were analyzed using log-linear models 
(Agresti, 2002) in SAS PROC CATMOD.JCB • VOLUME 178 • NUMBER 6 • 2007  1022
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